4-diazo-N,N-dimethyl-4H-imidazole-5-sulfonamide

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机磺酸及其衍生物
• 英文名称: 4-diazo-N,N-dimethyl-4H-imidazole-5-sulfonamide
• 英文别名: (5E)-5-diazo-N,N-dimethylimidazole-4-sulfonamide
• 化学式: C₅H₇N₅O₂S
• 分子量: 201.209
• InChiKey: NGRRFQDYBHRMRJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  72.5
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-diazo-N,N-dimethyl-4H-imidazole-5-sulfonamide 在 盐酸 、 水 、 sodium hydride 作用下， 以 乙酸乙酯 、 N,N-二甲基甲酰胺 、 甲苯 、 mineral oil 为溶剂， 反应 5.5h， 生成 N,N,3-trimethyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-sulfonamide
  参考文献：
  名称：

  [EN] 8 - SULFO - IMIDAZOTETRAZIN- 4 - ONE COMPOUNDS AND THEIR USE AS ANTICANCER DRUG
  [FR] COMPOSÉS 8-SULFO-IMIDAZOTÉTRAZIN-4-ONE ET LEUR UTILISATION EN TANT QUE MÉDICAMENT ANTICANCÉREUX

  摘要：

  提供具有化学式（I）及其药用可接受的盐、水合物或溶剂化合物（I）的其中B、X和Y的定义如本文所述。这些化合物在调节细胞增殖、抑制细胞周期进展和/或促进凋亡的方法中有用，并用于治疗增生性疾病。

  公开号：

  WO2012085501A1
• 作为产物：
  描述：

  5(4)-amino-N,N-dimethyl-1H-imidazole-4(5)-sulfonamide 在 盐酸 、 sodium nitrite 作用下， 以 水 为溶剂， 反应 0.83h， 以82%的产率得到4-diazo-N,N-dimethyl-4H-imidazole-5-sulfonamide
  参考文献：
  名称：

  [EN] 8 - SULFO - IMIDAZOTETRAZIN- 4 - ONE COMPOUNDS AND THEIR USE AS ANTICANCER DRUG
  [FR] COMPOSÉS 8-SULFO-IMIDAZOTÉTRAZIN-4-ONE ET LEUR UTILISATION EN TANT QUE MÉDICAMENT ANTICANCÉREUX

  摘要：

  提供具有化学式（I）及其药用可接受的盐、水合物或溶剂化合物（I）的其中B、X和Y的定义如本文所述。这些化合物在调节细胞增殖、抑制细胞周期进展和/或促进凋亡的方法中有用，并用于治疗增生性疾病。

  公开号：

  WO2012085501A1

文献信息

• LUNT E.; NEWTON CH. G.; SMITH CH.; STEVENS G. P.; STEVENS M. F. G.; STRAW+, J. MED. CHEM., 30,(1987) N 2, 357-366
  作者：LUNT E.、 NEWTON CH. G.、 SMITH CH.、 STEVENS G. P.、 STEVENS M. F. G.、 STRAW+

  DOI：——

  日期：——
• [EN] 8 - SULFO - IMIDAZOTETRAZIN- 4 - ONE COMPOUNDS AND THEIR USE AS ANTICANCER DRUG<br/>[FR] COMPOSÉS 8-SULFO-IMIDAZOTÉTRAZIN-4-ONE ET LEUR UTILISATION EN TANT QUE MÉDICAMENT ANTICANCÉREUX
  申请人：PHARMINOX LTD

  公开号：WO2012085501A1

  公开（公告）日：2012-06-28

  Compounds of formula (I) and pharmaceutically acceptable salts, hydrates or solvates thereof are provided (I) wherein B, X, and Y are as defined herein. The compounds are of use in methods of regulating cell proliferation, inhibiting cell cycle progression, and/or promoting apoptosis, and in the treatment of proliferative disorders.

  提供具有化学式（I）及其药用可接受的盐、水合物或溶剂化合物（I）的其中B、X和Y的定义如本文所述。这些化合物在调节细胞增殖、抑制细胞周期进展和/或促进凋亡的方法中有用，并用于治疗增生性疾病。
• Antitumor imidazotetrazines. 14. Synthesis and antitumor activity of 6- and 8-substituted imidazo[5,1-d]-1,2,3,5-tetrazinones and 8-substituted pyrazolo[5,1-d]-1,2,3,5-tetrazinones
  作者：Edward Lunt、Christopher G. Newton、Christopher Smith、Graham P. Stevens、Malcolm F. G. Stevens、Colin G. Straw、Roger J. A. Walsh、Peter J. Warren、Christian Fizames

  DOI：10.1021/jm00385a018

  日期：1987.2

  The systematic variation of the potent antitumor agent mitozolomide (1) is extended to cover alteration of substituents at positions 6 and 8 and to change the imidazo[5,1-d]-1,2,3,5-tetrazinone (1) skeleton to the isomeric pyrazolo-[5,1-d]-1,2,3,5-tetrazinone (17) skeleton. The series of eight 6-alkyl and 6-aralkyl derivatives of 1 showed optimal antitumor activity when the group was small or linear, but activity diminished as size and branching of this substituent increased. This may reflect altered transport characteristics, or failure of the enlarged derivatives to fit a binding site, or possibly a reduced tendency for the derivatives having bulky groups at position 6 to hydrolytically generate the putatively active triazenes (21). Testing of 14 derivatives of 1 differently substituted at position 8 revealed a complex structure-activity relationship, with good antitumor activity obtained for carbamoyl and sulfamoyl groups bearing small substituents. The 8-methylsulfonyl compound had noteworthy activity, but the 8-cyano, 8-nitro, and 8-phenyl derivatives were devoid of useful antitumor activity in these tests. From the limited number of pyrazolotetrazinones (17) reported here, it is suggested that the same conclusions as regards activity also hold true for this ring system.